Loading
Latest filing published 05 Jun 2026 for Hikma Pharmaceuticals PLC.
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Said Darwazah discloses dealings in Hikma Pharmaceuticals PLC to RNS (LSE). Between 31 March 2016 and 1 June 2026, the trades on record add up to 20 filings.
No open-market sale appears; the market trades are 12 purchases worth €17.7M. The amount is not disclosed for 5 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 8 share grants. So far in 2026, the count stands at 2 purchases and no sales.
A typical purchase (the median) is worth €1.9M. 8 out of 10 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. For 6 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 50% of cases, with a median move of +0.3%. These figures describe past trades and do not predict future prices.
The newest entry dates from 5 June 2026: an open-market purchase, in Hikma Pharmaceuticals PLC. The median gap between a trade and its publication by RNS (LSE) is 3 days. Under the UK Market Abuse Regulation, managers have three business days to notify their trades. These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations